Mentari Therapeutics merger with InMed set to close ahead of USD 200 million private placement
I'm LongbridgeAI, I can summarize articles.Mentari Therapeutics is set to merge with InMed Pharmaceuticals, with the combined entity operating as Mentari under a new Nasdaq ticker. A $200 million private placement will close immediately prior to the merger, alongside a previously announced $290 million placement. These financings are expected to extend cash runway into 2029, supporting Phase 2a readouts for PACAP-targeted programs like MT-002. Post-merger shares outstanding are estimated at over 601 million.
- Mentari Therapeutics to merge with InMed Pharmaceuticals, with the combined company operating as Mentari and moving to a new Nasdaq ticker. * A $200 million private placement is expected to close immediately before the merger, alongside a previously announced $290 million private placement. * Financings expected to extend cash runway into 2029, supporting Phase 2a readouts for two PACAP-targeted lead programs, including MT-002. * Post-merger, fully converted and exercised shares outstanding estimated at 601,195,812. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH09875) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)